Pen-Like device could help surgeons detect cancer in real time

NCT ID NCT07298083

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a handheld device called the MasSpec Pen can tell the difference between cancerous MPNST, benign neurofibromas, and normal tissue during surgery. About 60 people with MPNST or neurofibroma will take part. The goal is to see if the device is safe and accurate enough to help surgeons remove all cancer in one operation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MasSpec Pen (handheld mass spectrometry device)
What this could lead to: If successful, this could give surgeons a real-time tool to identify cancerous tissue during surgery, potentially improving tumor removal and reducing repeat surgeries.
What could go wrong: This is a small, early-stage study (60 participants) focused on feasibility and safety. The device may not prove accurate enough in larger, more diverse groups, and technical issues could arise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPNST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant peripheral nerve sheath tumor neurofibroma neurofibrosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPNST NEUROFIBROMAS

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77090, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.